![color me mine menlo park color me mine menlo park](https://static.mommypoppins.com/styles/image300x250/s3/img_7843_0.jpg)
From advances in psoriasis, where numerous therapies have been developed, we have learned that targeting different subunits in common molecular pathways can have drastically different clinical effects. “To improve treatment options for patients, it is important to focus on obtaining a better understanding of the role of specific disease mechanisms targeted by different groups of therapies, such as the various components of the Type 1 and Type 2 receptor complexes that regulate IL-4 and IL-13 signaling. “This is an encouraging time in atopic dermatitis with a variety of novel therapies becoming available,” commented Dr Shawn Kwatra, Associate Professor of Dermatology at the Johns Hopkins University School of Medicine. Dr Kwatra is a receptor pharmacologist and was trained with Nobel Laureate Dr Bob Lefkowitz.
![color me mine menlo park color me mine menlo park](https://edison.colormemine.com/wp-content/uploads/sites/57/2020/06/RW_Peck_ColoringPage-scaled.jpg)
Madan Kwatra, PhD, is the Director of the Molecular Pharmacology Laboratory in the Department of Anesthesiology at Duke University Medical Center.
Color me mine menlo park skin#
Dr Kwatra has been an author or co-author on over 180 publications and is a member of the Board of Directors of the Skin of Color Society. His areas of clinical expertise include atopic dermatitis, chronic pruritus, prurigo nodularis and dermatology for ethnic skin. Shawn Kwatra, MD, is an Associate Professor of Dermatology at the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Director of the Johns Hopkins Itch Center. Initial findings from the collaboration will be disclosed for presentation during the second half of 2022. The studies will also explore the downstream effects of specifically targeting IL-13Ra1 by eblasakimab and help to further the understanding of the biological relevance of IL-4 and IL-13 signaling. The research collaboration will evaluate the role of IL-13Ra1 in moderate-to-severe AD patient samples and will test how IL-13Ra1-mediated allergic, inflammatory and regulatory pathways are affected by eblasakimab’s selective targeting of the Type 2 receptor in contrast to a broader blockade of both the Type 1 and Type 2 receptors seen in current standards of care. and SINGAPORE, J(GLOBE NEWSWIRE) - ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has initiated a research collaboration with Dr Shawn Kwatra, as an advisor, from Johns Hopkins University School of Medicine and Dr Madan Kwatra from Duke University Medical Center to investigate the unique role of the IL-13Ra1 subunit, distinct from the role of other pathway components, in Type 2-mediated inflammatory diseases, specifically atopic dermatitis (AD).